| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Salmonella enterica | 10 | 2025 | 26 | 3.830 |
Why?
|
| Anti-Bacterial Agents | 12 | 2025 | 801 | 2.040 |
Why?
|
| Breast Neoplasms | 23 | 2021 | 1222 | 2.010 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 7 | 2025 | 60 | 1.930 |
Why?
|
| Thyroid Neoplasms | 7 | 2024 | 87 | 1.690 |
Why?
|
| Food Microbiology | 8 | 2015 | 43 | 1.480 |
Why?
|
| Bacterial Proteins | 6 | 2025 | 741 | 1.280 |
Why?
|
| Microbial Sensitivity Tests | 10 | 2025 | 206 | 1.130 |
Why?
|
| Biomarkers, Tumor | 10 | 2016 | 524 | 1.090 |
Why?
|
| Salmonella Infections | 5 | 2014 | 41 | 1.030 |
Why?
|
| Virulence Factors | 3 | 2024 | 86 | 1.010 |
Why?
|
| Sisomicin | 1 | 2025 | 1 | 0.900 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2024 | 3 | 0.870 |
Why?
|
| Interspersed Repetitive Sequences | 1 | 2024 | 12 | 0.860 |
Why?
|
| Immunohistochemistry | 15 | 2017 | 896 | 0.830 |
Why?
|
| Seafood | 4 | 2012 | 14 | 0.810 |
Why?
|
| Escherichia coli Infections | 1 | 2024 | 90 | 0.810 |
Why?
|
| Plasmids | 6 | 2016 | 294 | 0.730 |
Why?
|
| Drug Resistance, Bacterial | 4 | 2025 | 96 | 0.700 |
Why?
|
| Carcinoma, Ductal, Breast | 5 | 2014 | 44 | 0.670 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2014 | 39 | 0.660 |
Why?
|
| Salmonella Food Poisoning | 2 | 2013 | 3 | 0.650 |
Why?
|
| Neoplasm Proteins | 4 | 2009 | 285 | 0.620 |
Why?
|
| Environmental Microbiology | 3 | 2014 | 15 | 0.580 |
Why?
|
| Adenocarcinoma, Follicular | 2 | 2009 | 6 | 0.520 |
Why?
|
| Serogroup | 1 | 2016 | 35 | 0.490 |
Why?
|
| RNA-Binding Proteins | 2 | 2009 | 447 | 0.450 |
Why?
|
| Salmonella | 1 | 2015 | 45 | 0.440 |
Why?
|
| Fallopian Tubes | 1 | 2014 | 13 | 0.420 |
Why?
|
| Uterine Diseases | 1 | 2014 | 9 | 0.420 |
Why?
|
| Choristoma | 1 | 2014 | 24 | 0.420 |
Why?
|
| Neoplasms, Fibroepithelial | 1 | 2014 | 3 | 0.410 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 58 | 0.410 |
Why?
|
| Minocycline | 2 | 2013 | 28 | 0.410 |
Why?
|
| Poultry Diseases | 1 | 2013 | 3 | 0.410 |
Why?
|
| Salmonella enteritidis | 1 | 2013 | 5 | 0.400 |
Why?
|
| Animal Husbandry | 1 | 2013 | 10 | 0.400 |
Why?
|
| Salmonella Infections, Animal | 1 | 2013 | 9 | 0.400 |
Why?
|
| Humans | 46 | 2024 | 65124 | 0.400 |
Why?
|
| Antiporters | 1 | 2013 | 7 | 0.400 |
Why?
|
| Integrons | 2 | 2009 | 3 | 0.370 |
Why?
|
| Phylogeny | 5 | 2013 | 388 | 0.360 |
Why?
|
| DNA, Bacterial | 8 | 2014 | 261 | 0.350 |
Why?
|
| Female | 30 | 2024 | 34016 | 0.350 |
Why?
|
| Food Contamination | 3 | 2011 | 23 | 0.350 |
Why?
|
| Fluoroquinolones | 1 | 2011 | 33 | 0.350 |
Why?
|
| Paraffin Embedding | 2 | 2007 | 18 | 0.320 |
Why?
|
| Hemangioma | 1 | 2010 | 27 | 0.320 |
Why?
|
| Breast Diseases | 1 | 2010 | 45 | 0.320 |
Why?
|
| Stromal Cells | 1 | 2010 | 78 | 0.310 |
Why?
|
| Taiwan | 3 | 2016 | 14 | 0.290 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2017 | 67 | 0.290 |
Why?
|
| Sequence Analysis, DNA | 5 | 2014 | 414 | 0.260 |
Why?
|
| Gene Amplification | 2 | 2009 | 27 | 0.260 |
Why?
|
| Neoplasms, Ductal, Lobular, and Medullary | 1 | 2007 | 3 | 0.260 |
Why?
|
| Breast | 2 | 2015 | 191 | 0.250 |
Why?
|
| Citrus sinensis | 1 | 2006 | 11 | 0.250 |
Why?
|
| Adenoma | 2 | 2007 | 70 | 0.250 |
Why?
|
| Beverages | 1 | 2006 | 70 | 0.240 |
Why?
|
| Receptors, Progesterone | 6 | 2011 | 110 | 0.230 |
Why?
|
| Gentamicins | 1 | 2025 | 24 | 0.220 |
Why?
|
| Ear Canal | 1 | 2004 | 4 | 0.220 |
Why?
|
| Neoplasms, Fibrous Tissue | 1 | 2004 | 2 | 0.220 |
Why?
|
| Ear Neoplasms | 1 | 2004 | 6 | 0.220 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2024 | 699 | 0.220 |
Why?
|
| Genomic Islands | 1 | 2024 | 8 | 0.220 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2024 | 14 | 0.220 |
Why?
|
| Gram-Positive Bacteria | 2 | 2004 | 35 | 0.220 |
Why?
|
| Genome, Bacterial | 1 | 2024 | 66 | 0.210 |
Why?
|
| Polymerase Chain Reaction | 6 | 2014 | 513 | 0.210 |
Why?
|
| Whole Genome Sequencing | 1 | 2024 | 85 | 0.210 |
Why?
|
| Vietnam | 2 | 2016 | 185 | 0.200 |
Why?
|
| Gram-Negative Bacteria | 1 | 2003 | 56 | 0.200 |
Why?
|
| Urinary Tract Infections | 1 | 2024 | 97 | 0.200 |
Why?
|
| RNA, Bacterial | 1 | 2003 | 73 | 0.200 |
Why?
|
| Parathyroid Neoplasms | 1 | 2003 | 5 | 0.190 |
Why?
|
| Parathyroid Glands | 1 | 2003 | 9 | 0.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 583 | 0.190 |
Why?
|
| Calcitonin | 1 | 2003 | 17 | 0.190 |
Why?
|
| Hemangiosarcoma | 2 | 2015 | 24 | 0.190 |
Why?
|
| Hyperplasia | 3 | 2010 | 90 | 0.190 |
Why?
|
| Gene Expression Profiling | 3 | 2014 | 794 | 0.190 |
Why?
|
| Fluorescence Polarization | 3 | 2024 | 32 | 0.180 |
Why?
|
| Thyroid Gland | 2 | 2024 | 83 | 0.180 |
Why?
|
| Serotyping | 2 | 2015 | 52 | 0.180 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 3 | 2013 | 11 | 0.180 |
Why?
|
| Biopsy, Needle | 2 | 2013 | 134 | 0.170 |
Why?
|
| Middle Aged | 14 | 2017 | 18267 | 0.170 |
Why?
|
| Genomics | 1 | 2024 | 384 | 0.170 |
Why?
|
| Escherichia coli | 2 | 2025 | 714 | 0.170 |
Why?
|
| Molecular Sequence Data | 5 | 2011 | 1979 | 0.160 |
Why?
|
| Mycobacterium | 3 | 2005 | 37 | 0.160 |
Why?
|
| Kidney | 2 | 2013 | 451 | 0.150 |
Why?
|
| Catfishes | 2 | 2009 | 2 | 0.140 |
Why?
|
| Keratins | 2 | 2016 | 31 | 0.140 |
Why?
|
| Aeromonas | 2 | 2009 | 6 | 0.140 |
Why?
|
| Adult | 11 | 2015 | 17356 | 0.140 |
Why?
|
| Carcinoma | 2 | 2012 | 130 | 0.140 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2017 | 2 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2017 | 19 | 0.140 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 37 | 0.130 |
Why?
|
| Rare Diseases | 1 | 2017 | 45 | 0.130 |
Why?
|
| Receptors, Estrogen | 4 | 2011 | 130 | 0.130 |
Why?
|
| Indonesia | 1 | 2016 | 10 | 0.120 |
Why?
|
| Pleural Effusion | 2 | 2007 | 39 | 0.120 |
Why?
|
| Antibodies | 1 | 2016 | 187 | 0.120 |
Why?
|
| China | 1 | 2016 | 176 | 0.120 |
Why?
|
| Aged | 8 | 2015 | 14958 | 0.120 |
Why?
|
| beta-Lactam Resistance | 1 | 2015 | 4 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 2017 | 351 | 0.110 |
Why?
|
| beta-Lactamases | 1 | 2015 | 18 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2015 | 21 | 0.110 |
Why?
|
| Cluster Analysis | 2 | 2013 | 261 | 0.110 |
Why?
|
| Sequence Homology | 1 | 2014 | 21 | 0.110 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 152 | 0.110 |
Why?
|
| Prognosis | 5 | 2014 | 1785 | 0.110 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 2 | 2005 | 18 | 0.110 |
Why?
|
| Genetic Complementation Test | 1 | 2014 | 67 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2017 | 161 | 0.110 |
Why?
|
| Cystadenoma, Serous | 1 | 2014 | 3 | 0.110 |
Why?
|
| O Antigens | 1 | 2014 | 4 | 0.110 |
Why?
|
| Cholera Vaccines | 1 | 2014 | 3 | 0.110 |
Why?
|
| Vibrio cholerae O1 | 1 | 2014 | 6 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 113 | 0.100 |
Why?
|
| Cholera | 1 | 2014 | 16 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2011 | 415 | 0.100 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2014 | 2 | 0.100 |
Why?
|
| Cysts | 1 | 2014 | 44 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 312 | 0.100 |
Why?
|
| Poultry | 1 | 2013 | 9 | 0.100 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 73 | 0.100 |
Why?
|
| Needles | 2 | 2013 | 64 | 0.100 |
Why?
|
| Blotting, Southern | 3 | 2008 | 56 | 0.100 |
Why?
|
| Mesothelioma | 1 | 2013 | 28 | 0.100 |
Why?
|
| Tetracycline | 1 | 2013 | 22 | 0.100 |
Why?
|
| Drug Resistance, Microbial | 1 | 2013 | 47 | 0.100 |
Why?
|
| Antibodies, Bacterial | 1 | 2014 | 181 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2014 | 312 | 0.100 |
Why?
|
| Cytoplasm | 1 | 2014 | 283 | 0.100 |
Why?
|
| HeLa Cells | 1 | 2014 | 541 | 0.100 |
Why?
|
| Male | 5 | 2024 | 31042 | 0.100 |
Why?
|
| Lung Neoplasms | 2 | 2013 | 704 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 244 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2011 | 991 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 166 | 0.090 |
Why?
|
| Genetic Variation | 2 | 2013 | 394 | 0.090 |
Why?
|
| Coloring Agents | 1 | 2012 | 50 | 0.090 |
Why?
|
| Cell Cycle | 1 | 2014 | 398 | 0.090 |
Why?
|
| Nalidixic Acid | 1 | 2012 | 3 | 0.090 |
Why?
|
| DNA Topoisomerase IV | 1 | 2012 | 3 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 114 | 0.090 |
Why?
|
| Diagnostic Errors | 2 | 2017 | 105 | 0.090 |
Why?
|
| DNA Gyrase | 1 | 2012 | 10 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2012 | 52 | 0.090 |
Why?
|
| Paget's Disease, Mammary | 1 | 2011 | 3 | 0.090 |
Why?
|
| United Kingdom | 1 | 2012 | 85 | 0.090 |
Why?
|
| Thailand | 1 | 2012 | 91 | 0.090 |
Why?
|
| Quinolones | 1 | 2012 | 25 | 0.090 |
Why?
|
| Epithelial Cells | 1 | 2014 | 410 | 0.090 |
Why?
|
| SEER Program | 1 | 2011 | 75 | 0.090 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2011 | 12 | 0.090 |
Why?
|
| Salmonella typhimurium | 1 | 2012 | 85 | 0.080 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 624 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2013 | 6862 | 0.080 |
Why?
|
| Integrin beta4 | 2 | 2008 | 35 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2014 | 630 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2011 | 190 | 0.080 |
Why?
|
| Vimentin | 1 | 2010 | 19 | 0.080 |
Why?
|
| Antigens, CD34 | 1 | 2010 | 53 | 0.080 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2011 | 61 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 286 | 0.080 |
Why?
|
| Tomography, Optical Coherence | 1 | 2012 | 235 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 186 | 0.080 |
Why?
|
| Methylene Blue | 2 | 2024 | 23 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 287 | 0.080 |
Why?
|
| Hong Kong | 1 | 2008 | 4 | 0.070 |
Why?
|
| Philippines | 1 | 2008 | 6 | 0.070 |
Why?
|
| Actins | 1 | 2010 | 264 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 373 | 0.070 |
Why?
|
| Receptor, Notch1 | 1 | 2008 | 67 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 1163 | 0.070 |
Why?
|
| Phenotype | 2 | 2009 | 1232 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2011 | 506 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2008 | 116 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2011 | 354 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 2 | 2008 | 108 | 0.070 |
Why?
|
| Phyllodes Tumor | 1 | 2007 | 5 | 0.070 |
Why?
|
| Papilloma, Intraductal | 1 | 2007 | 6 | 0.060 |
Why?
|
| Axilla | 1 | 2007 | 18 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2007 | 33 | 0.060 |
Why?
|
| Base Sequence | 2 | 2006 | 1329 | 0.060 |
Why?
|
| Carcinoma, Lobular | 1 | 2007 | 26 | 0.060 |
Why?
|
| Oxygenases | 2 | 2004 | 8 | 0.060 |
Why?
|
| Carcinoma in Situ | 1 | 2007 | 36 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2007 | 90 | 0.060 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2007 | 27 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 91 | 0.060 |
Why?
|
| Tetracyclines | 1 | 2006 | 6 | 0.060 |
Why?
|
| Mastectomy | 1 | 2007 | 56 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 1566 | 0.060 |
Why?
|
| Fixatives | 1 | 2006 | 16 | 0.060 |
Why?
|
| Formaldehyde | 1 | 2006 | 33 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 102 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 110 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 2 | 2021 | 401 | 0.060 |
Why?
|
| Diarrhea, Infantile | 1 | 2005 | 2 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2005 | 28 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2009 | 1575 | 0.060 |
Why?
|
| Fluid Therapy | 1 | 2005 | 46 | 0.060 |
Why?
|
| Animals | 6 | 2013 | 21324 | 0.060 |
Why?
|
| Uteroglobin | 1 | 2004 | 7 | 0.060 |
Why?
|
| Antibodies, Neoplasm | 1 | 2004 | 27 | 0.060 |
Why?
|
| Operon | 1 | 2004 | 31 | 0.050 |
Why?
|
| Zinc | 1 | 2005 | 95 | 0.050 |
Why?
|
| Phthalic Acids | 1 | 2004 | 41 | 0.050 |
Why?
|
| Cytodiagnosis | 1 | 2024 | 46 | 0.050 |
Why?
|
| Chloroform | 1 | 2003 | 4 | 0.050 |
Why?
|
| Octoxynol | 1 | 2003 | 11 | 0.050 |
Why?
|
| Detergents | 1 | 2003 | 34 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 366 | 0.050 |
Why?
|
| Solvents | 1 | 2003 | 60 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 710 | 0.050 |
Why?
|
| CD57 Antigens | 1 | 2003 | 2 | 0.050 |
Why?
|
| Synaptophysin | 1 | 2003 | 6 | 0.050 |
Why?
|
| Chromogranin A | 1 | 2003 | 8 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2003 | 65 | 0.050 |
Why?
|
| Chromogranins | 1 | 2003 | 12 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2007 | 1036 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 327 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 5612 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2003 | 342 | 0.040 |
Why?
|
| United States | 1 | 2014 | 8097 | 0.040 |
Why?
|
| Disease Progression | 1 | 2005 | 1219 | 0.040 |
Why?
|
| Bangladesh | 2 | 2014 | 25 | 0.040 |
Why?
|
| Optical Imaging | 1 | 2021 | 77 | 0.040 |
Why?
|
| Cloning, Molecular | 3 | 2005 | 384 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2011 | 544 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 587 | 0.040 |
Why?
|
| Neck Dissection | 1 | 2017 | 18 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2017 | 9 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 41 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 2017 | 35 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2011 | 222 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2015 | 26 | 0.030 |
Why?
|
| Antibody-Producing Cells | 1 | 2014 | 12 | 0.030 |
Why?
|
| Vaccines, Inactivated | 1 | 2014 | 14 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2015 | 83 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2014 | 116 | 0.030 |
Why?
|
| Immunization, Secondary | 1 | 2014 | 52 | 0.030 |
Why?
|
| Kidney Medulla | 1 | 2013 | 7 | 0.020 |
Why?
|
| Kidney Cortex | 1 | 2013 | 10 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2013 | 23 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2014 | 102 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 371 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2012 | 34 | 0.020 |
Why?
|
| Optics and Photonics | 1 | 2012 | 13 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 465 | 0.020 |
Why?
|
| Swine | 1 | 2013 | 394 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 240 | 0.020 |
Why?
|
| Capsicum | 1 | 2011 | 1 | 0.020 |
Why?
|
| Aromatase Inhibitors | 1 | 2011 | 11 | 0.020 |
Why?
|
| Vaccination | 1 | 2014 | 375 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 563 | 0.020 |
Why?
|
| Nitriles | 1 | 2011 | 82 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2011 | 94 | 0.020 |
Why?
|
| Triazoles | 1 | 2011 | 63 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2011 | 56 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 309 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2012 | 422 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1113 | 0.020 |
Why?
|
| Consumer Product Safety | 1 | 2009 | 12 | 0.020 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2009 | 25 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 432 | 0.020 |
Why?
|
| Cattle | 1 | 2010 | 320 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2012 | 299 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 405 | 0.020 |
Why?
|
| Survival Rate | 1 | 2011 | 844 | 0.020 |
Why?
|
| Virulence | 1 | 2009 | 199 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 363 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2008 | 40 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2008 | 49 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1015 | 0.020 |
Why?
|
| Keratin-6 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Keratin-5 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 2619 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 297 | 0.020 |
Why?
|
| Pigmentation | 1 | 2007 | 25 | 0.020 |
Why?
|
| Acne Vulgaris | 1 | 2007 | 23 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2007 | 17 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 2703 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2006 | 26 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 701 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2006 | 11 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 140 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2006 | 105 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2483 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2005 | 42 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2005 | 39 | 0.010 |
Why?
|
| Rehydration Solutions | 1 | 2005 | 3 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2008 | 430 | 0.010 |
Why?
|
| Placebos | 1 | 2005 | 73 | 0.010 |
Why?
|
| Massachusetts | 1 | 2011 | 2145 | 0.010 |
Why?
|
| Urine | 1 | 2005 | 46 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 234 | 0.010 |
Why?
|
| Mammaglobin A | 1 | 2004 | 2 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2005 | 300 | 0.010 |
Why?
|
| Feces | 1 | 2005 | 118 | 0.010 |
Why?
|
| Synteny | 1 | 2004 | 24 | 0.010 |
Why?
|
| Gene Order | 1 | 2004 | 33 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 2004 | 115 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2004 | 169 | 0.010 |
Why?
|
| Body Weight | 1 | 2005 | 376 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2004 | 201 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 4810 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 663 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2005 | 739 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 856 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2284 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 1589 | 0.010 |
Why?
|
| Neoplasms | 1 | 2012 | 1367 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 5429 | 0.010 |
Why?
|
| Infant | 1 | 2005 | 1693 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 1559 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2008 | 3149 | 0.010 |
Why?
|
| Hospitalization | 1 | 2005 | 1392 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 3762 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 5788 | 0.010 |
Why?
|